Circassia plans Phase III of cat and other allergy vaccines
This article was originally published in Scrip
Executive Summary
Specialty UK biotech company Circassia plans to progress its ToleroMune cat allergy vaccine into Phase III in the first half 2012 after the follow-up data from its fourth Phase II trial of the product confirmed significant symptom reductions after one year.